Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review
Annals of Hematology · 2025-07 · 104 (7) · 3889-3892
DOI: 10.1007/s00277-025-06388-w ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 27.06.2025. Verfasst von Ted M Getz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT, USA. theodore.getz@yale.edu. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-kit, Translocation, Genetic, Chromosomes, Human, Pair 8. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Acute myeloid leukemia (AML) with t(8;21) is a subset of core binding factor AML and is considered to be favorable risk disease in patients receiving intensive cytarabine based chemotherapy. However, relapse remains a significant clinical challenge. Mutations in KIT , which frequently co-occur in t(8;21) AML, have been associated with worse relapse free and overall survival. Avapritinib is a novel tyrosine kinase inhibitor targeting KIT mutations that is approved for systemic mastocytosis but doesn’t currently have an established role in the treatment of AML. We present a case of a patient with extensively treated KIT D816H-mutated t(8;21) AML who experienced relapse after an allogeneic hematopoietic stem cell transplant and achieved a deep remission rapidly with avapritinib monotherapy. This case highlights the potential role of avapritinib as a targeted therapy for relapsed t(8;21) AML with KIT mutations, warranting further clinical investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT, USA. theodore.getz@yale.edu.
- Department of Hematology and Oncology, Danbury Hospital, Nuvance Health, Danbury, CT, USA.
- Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT, USA.
Zitieren
APA
Getz, T. M., Bakirhan, K., Seropian, S., & Shallis, R. M. (2025). Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review. Annals of Hematology, 104(7), 3889-3892. https://doi.org/10.1007/s00277-025-06388-w
Vancouver
Getz TM, Bakirhan K, Seropian S, Shallis RM. Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review. Annals of Hematology. 2025;104(7):3889-3892. doi:10.1007/s00277-025-06388-w
BibTeX
@article{Getz2025,
author = {Getz, Ted M and Bakirhan, Kamila and Seropian, Stuart and Shallis, Rory M},
title = {Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemia, a case report and literature review},
journal = {Annals of Hematology},
year = {2025},
volume = {104},
number = {7},
pages = {3889--3892},
doi = {10.1007/s00277-025-06388-w}
}
EUVIMED